Search Results

L7 Informatics CEO, Vasu Rangadass, Ph.D., examines the architectural principle separating pharmaceutical AI experimentation from enterprise-scale deployment.

L7 CEO Vasu Rangadass, Ph.D., argues that regulated process industries have reached the limits of point-solution modernization and must pivot to unified orchestration to unlock the promise of agentic AI.

Strong science, lower costs and growing capital networks are putting Spain and Portugal on the biotech investment map, even as structural bottlenecks persist, according to two investors.

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing through trials in lung cancer. But the potential of these drugs may be highest in cancers where angiogenesis and immune escape are tightly intertwined.

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech.

Partnership to Provide Life Science Companies with Turnkey Solution for Award Winning Capital Market Access, Best-In-Class Regulatory Affairs Management, Clinical Trial Management Services, and Investor Engagement